pulseline logo

A MESSAGE FROM IAN BURGESS, CEO, MTAA

On behalf of the MedTech industry, MTAA is collating and sharing information on changes in the supply chain and emerging issues; significant pain points for MedTech businesses; and how company business practices are evolving to respond to COVID-19, particularly in the areas of work-from-home, travel restrictions, face-to-face meetings and business continuity planning.

MTAA is working closely with the government to address emerging supply chain impacts on business and broader industry as a result of COVID-19. The industry is represented on a regular roundtable convened by the Minister for Industry, Science and Technology, together with other key stakeholders. An initial meeting was held last week, with the second meeting held on Thursday 19 March.

The roundtable is being held to discuss emerging supply chain impacts on business and broader industry as a result of COVID-19. Discussion will focus on what sectors are being impacted by supply chain issues, including how business is managing these challenges. The Minister welcomes any insights or suggestions about the best way forward to ensure business and industry are supported during this time.

MTAA is also engaging closely with the Chief Medical Office and the Federal Health Minister. Most recently this has been regarding the Government’s immediate priorities – the supply of respirators, reagents for testing and also masks. We have also facilitated relevant companies engaging with the Government regarding supply.

These are challenging times for our community, our industry and please take care of yourself and others.

MTAA PRECAUTIONARY MEASURES

Our events that were scheduled for the near future have been postponed and we plan to conduct webinar events where possible. Our face-to-face training courses, Operating Theatre Protocols, have been postponed.

All committee meetings are now taking place via teleconference/videoconferencing and the majority of MTAA staff are working from home.

Related Stories

News

You have subscribed